Managing Director & Partner
Megan DeFauw is a core member of Boston Consulting Group’s Health Care and Operations practices. She focuses on biopharma and medtech manufacturing and supply chain. Since joining BCG in 2011, Megan has worked extensively in strategy and operations topics including network design, quality, organization design, large-scale transformation, post-merger integration, and divestitures. Megan leads the firm’s work in quality for North America, as well as for cost transformation in health care operations.
Megan has worked with pharmaceutical and medtech clients across all phases of acquisitions and divestitures, as well as manufacturing network strategy and redesign, operations transformation, and quality remediation and transformation.
Through carve-outs, companies can create value, streamline portfolios, and reduce complexity. But the ultimate success of a deal hinges on focused, proactive execution.
Acquirers need to plan their integrations carefully and act quickly, but too often they delay decision making and destroy value.
As the current crisis demonstrates, biopharma and medtech companies need to safeguard their networks against unanticipated disruptions. Here’s how.
To address flaws exposed by the pandemic, companies should accelerate efforts to revamp their worldwide manufacturing and sourcing networks—even if that means extra cost.